VioOne HIV Profile Supplemental Assay is as an additional and more specific test to confirm the presence of antibodies in specimens repeatedly reactive in diagnostic procedures. Credit: Shameer Pk from Pixabay.

US-based medical device company Avioq has received approval from the Food and Drug Administration (FDA) for its VioOne HIV Profile Supplemental Assay.

The HIV Profile assay is an enzyme-linked immunosorbent assay (ELISA).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is intended for the confirmation and differentiation of individual antibodies directed to several gene products of HIV-1 (Group M and Group O), as well as HIV-2 in human serum or plasma.

The assay can be used as an additional and more specific test to confirm the presence of antibodies in specimens repeatedly reactive in diagnostic procedures.

In 2014, the Centers for Disease Control and Prevention (CDC) launched a new algorithm for HIV testing.

The second step of CDC’s algorithm comprises a supplemental assay that is capable of detecting and differentiating HIV-1 and HIV-2 for confirmation of repeatedly reactive HIV-1 / HIV-2 screening results.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Such confirmatory testing was conducted using Western Blot until HIV 1/2 immunochromatographic assay was introduced.

Avioq’s HIV Profile assay, which aligns with the CDC algorithm, is considered to be a better alternative to these tests.

Avioq CEO Dr Chamroen Chetty said: “We are pleased to provide this state of the art HIV Profile assay to laboratories in the US. The performance has been established in years of clinical trials and we are pleased with the results.

“We are also looking for distribution partners to expand the global availability of our CE Mark version of the assay.”

Located in Research Triangle Park, North Carolina, Avioq specialises in the development and marketing of immunodiagnostic products.

Meanwhile, last month FDA approved Roche’s cobas HIV-1/HIV-2 Qualitative test for use on fully automated cobas 6800/8800 Systems in the US.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact